Vaccine Info

ACI-35.030 Alzheimer’s Disease Vaccine

Authored by
Staff
Last reviewed
February 12, 2021
Fact checked by
Robert Carlson, MD
Share

ACI-35.030 Alzheimer’s Disease Vaccine Description

ACI-35.030 Alzheimer’s Disease vaccine candidate is designed to elicit antibodies against phosphorylated pathological Tau protein. It is designed to reduce and facilitate the clearance of related Tau aggregates, slowing the progression of Tau-pathology and/or treating the underlying Tauopathy.

ACI-35.030 is a first-in-class vaccine candidate designed to generate a specific antibody response against pTau proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology, which is a major hallmark of AD.

On February 11, 2021, Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population, with very high antigen-specific titers. Importantly, it generated a much stronger antibody response than a direct injection of exogenous antibodies. As pathological pTau is present as a precursor many years before Tau accumulation in the brain is detectable via brain imaging, such results highlight the significant promise of ACI-35.030 as an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease. We look forward to continuing to advance ACI-35.030 in our collaboration with Janssen Pharmaceuticals, Inc., as we aim to bring this potentially breakthrough vaccine to patients.”

LAUSANNE, Switzerland-based AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.

ACI-35.030 Alzheimer’s Disease Vaccine Indication

ACI-35.030 Alzheimer’s Disease Vaccine is indicated to reduce the spread and seeding of Tau pathology, a major hallmark of AD.

Immunization with anti-Tau vaccines has become an important strategy for treating AD and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030, which is being developed in collaboration with Janssen Pharmaceuticals, Inc., is the first AD vaccine candidate designed to generate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology throughout the brain, says the company.

ACI-35.030 Alzheimer’s Disease Vaccine News

February 11, 2021 - AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study “These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population, with very high antigen-specific titers. Importantly, it generated a much stronger antibody response than a direct injection of exogenous antibodies. As pathological pTau is present as a precursor many years before Tau accumulation in the brain is detectable via brain imaging, such results highlight the significant promise of ACI-35.030 as an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease. We look forward to continuing to advance ACI-35.030 in our collaboration with Janssen Pharmaceuticals, Inc., as we aim to bring this potentially breakthrough vaccine to patients," said Prof. Andrea Pfeifer, CEO of AC Immune SA.

January 25, 2021 - Barron's article: The Covid-19 Vaccine Offers a Road Map for Tackling Dementia. Here’s How.

July 16, 2020 - AC Immune SA announced the initiation of the second-highest dosing group in the Company’s Phase 1b/2a clinical trial evaluating ACI-35.030 to treat Alzheimer’s disease (AD). The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity result from the initial dosing group.

May 4, 2020 - Dear Investor, 2020 continues to be an important and eventful year for AC Immune and the entire field of neurodegenerative diseases, even in the context of the challenges posed by the Covid-19 pandemic. With the publication of our Q1 2020 results, we have again confirmed our strong cash position of CHF 277.9 million, which provides the Company with a solid foundation and a cash runway extending through at least Q1 2024, without including any potential future milestone payments from partnerships. Moving forward, we remain on track to meet multiple value-creating milestones this year, with five clinical readouts expected. Of these readouts, we are particularly excited about the expected announcement of the first Phase 2 proof-of-concept data for semorinemab, an anti-Tau antibody, achieved through our partnership with Genentech, a member of the Roche group.

ACI-35.030 Alzheimer’s Disease Vaccine Clinical Trials

Clinical Trial NCT04445831: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Tau Targeted Vaccines in 32 Participants With Early Alzheimer's Disease - Last update posted on October 19, 2020

Interim data from the Phase 1b/2a study showed: Anti-Tau IgG response preferentially targets phosphorylated Tau in all patients; 100% of patients demonstrated an anti-pTau IgG response after the 1st injection for both lowest and second highest dosages; Very high anti-pTau IgG titers observed following injection; Anti-pTau IgM response was also elicited in all patients for both doses; ACI-35.030 was safe and well-tolerated with no clinically relevant safety concerns observed to date.

Estimated Study completion date - October 31, 2023

Clinical Trials

No clinical trials found